CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
血液系统恶性肿瘤患者造血细胞移植后或 CAR-T 细胞治疗后的疫苗接种时间表建议与更新
英文原题：Vaccine schedule recommendations and updates for patients with hematologic malignancy post-hematopoietic cell transplant or CAR T-cell therapy.
查看英文原题
Vaccine schedule recommendations and updates for patients with hematologic malignancy post-hematopoietic cell transplant or CAR T-cell therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
在接受造血细胞移植（HCT）或细胞治疗后进行再接种是患者支持性治疗的支柱，具有降低与疫苗可预防感染相关的发病率和死亡率的潜力。本综述综合了国内、国际及专家共识的HCT后疫苗接种计划，并呈现了关于新型肺炎球菌疫苗、重组带状疱疹疫苗和2019冠状病毒病疫苗在血液恶性肿瘤患者中疗效的证据。细胞治疗后再次接种的定义尚不明确。本综述强调了关于疫苗反应不佳、细胞治疗后血清阳性率保持以及再接种最佳时机的重要考虑因素。未来的研究应评估新型疫苗配方和/或疫苗接种计划在HCT和细胞治疗后患者中的免疫原性和真实世界有效性，包括分析与细胞治疗靶点相关的疫苗反应。
展开英文摘要原文
Revaccination after receipt of a hematopoietic cell transplant (HCT) or cellular therapies is a pillar of patient supportive care, with the potential to reduce morbidity and mortality linked to vaccine-preventable infections. This review synthesizes national, international, and expert consensus vaccination schedules post-HCT and presents evidence regarding the efficacy of newer vaccine formulations for pneumococcus, recombinant zoster vaccine, and coronavirus disease 2019 in patients with hematological malignancy.
Revaccination post-cellular therapies are less well defined. This review highlights important considerations around poor vaccine response, seroprevalence preservation after cellular therapies, and the optimal timing of revaccination. Future research should assess the immunogenicity and real-world effectiveness of new vaccine formulations and/or vaccine schedules in patients post-HCT and cellular therapy, including analysis of vaccine response that relates to the target of cellular therapies.
论文信息
- 作者
- Reynolds G、Hall VG、Teh BW
- 单位
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.Australia
- 文献类型
- 综述
- 期刊
- Transplant infectious disease : an official journal of the Transplantation Society2023 Nov
- 原文标识
- PubMed 37515788 · DOI 10.1111/tid.14109
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →